Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150596 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7857566 | 0.79 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL926606 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL14808336 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14357370 | 0.75 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL12859809 | 0.75 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL927482 | 0.75 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL130928 | 0.74 | — | — | |
| SCHEMBL15199621 | 0.74 | — | — | |
| SCHEMBL19321817 | 0.73 | NR3C1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4015513-A1 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| US-8247596-B2 | Halogen-containing organosulfur compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247596-B2 | Halogen-containing organosulfur compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20110160251-A1 | ANIMAL ECTOPARASITE CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100160422-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160422-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160251-A1 | ANIMAL ECTOPARASITE CONTROL COMPOSITION | ADIPOR1, ADIPOR2, PLIN3 | ALDH1A1 2168/4885CYP2C9 1504/4885CYP2C19 2067/4885 |
| US-20100160422-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | C5, C1S, C9 | ALDH1A1 1797/4885CYP2C9 382/4885CYP2C19 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.